Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 6Unknown 2Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 124Thoracic 105Breast 99Genitourinary 94Tumor-Agnostic 88Dermatologic 71Head & Neck 48Gynecologic 40CNS 33Sarcoma 28Lymphoid 15Endocrine 12Other solid neoplasm 7Other hematologic neoplasm 7NET 5Plasma cell 3Myeloid 2Classical hematology 2

Conditions

Anemia 43Anemia, Refractory, with Excess of Blasts 40Leukemia, Myeloid, Acute 38Myelodysplastic Syndromes 36Leukemia 34Neoplasms 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Multiple Myeloma 25Thrombocytopenia 23Leukemia, Lymphocytic, Chronic, B-Cell 21Primary Myelofibrosis 20Lymphoma 20Lymphoma, Non-Hodgkin 19Leukemia, Myelomonocytic, Chronic 18Venous Thromboembolism 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Hodgkin Disease 16Myeloproliferative Disorders 15Lymphoma, Mantle-Cell 14Anemia, Aplastic 14Anemia, Refractory 13Lymphoma, Follicular 12Hematologic Neoplasms 12Lymphoma, Large B-Cell, Diffuse 11Congenital Abnormalities 10Neoplasms, Plasma Cell 9Myelodysplastic-Myeloproliferative Diseases 9Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Myeloid, Chronic-Phase 9Burkitt Lymphoma 9

Interventions

venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1cabozantinib 1cabazitaxel 1bicalutamide 1abiraterone 1abemaciclib 1XRP6258 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × Classical hematology × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00931606 2023-09-13

MK-7962-012

Merck Sharp & Dohme LLC

Phase 2 Terminated
30 enrolled 32 charts
Classical hematology

Anemia, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡